BioAge Labs today revealed plans to raise up to $75.0 million through an underwritten public offering of common shares, with joint book-running managers Goldman Sachs & Co. LLC, Piper Sandler and Citigroup leading the deal. BioAge has granted the underwriters a 30-day option to purchase up to an additional $11.25 million of shares. Net proceeds, together with existing cash, cash equivalents and marketable securities, will support ongoing research and clinical development of lead programs BGE-102, NLRP3 and APJ, finance manufacturing scale-up, pay down indebtedness and cover working capital and general corporate expenses. The offering is being made under an effective Form S-3 registration statement, and preliminary offering documents will be filed with the SEC.

BioAge is extending its BGE-102 NLRP3 inhibitor program into ophthalmology with a Phase 1b/2a proof-of-concept trial in patients with diabetic macular edema (DME), set to begin in mid-2026. In its ongoing Phase 1 SAD/MAD study, BGE-102 has shown favorable tolerability and robust reductions in inflammatory biomarkers—hsCRP, IL-6 and IL-1β—with additional MAD cohorts in obese participants anticipated in the first half of 2026. The DME trial will evaluate monotherapy and combination regimens against a VEGF inhibitor, using percent change in intraocular IL-6 as the primary endpoint, plus exploratory measures of best-corrected visual acuity and central subfield thickness. Topline DME data are expected in mid-2027, running parallel to the Phase 2a cardiovascular risk readout in the second half of 2026.